Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database

Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database

A better understanding of immune-related adverse events is essential for the early detection and appropriate management of these phenomena. We conducted an observational study of cases recorded at the French reference center for hypereosinophilic syndromes and in the French national pharmacovigilanc...

Full description

Bibliographic Details
Main Authors: Quentin Scanvion, Johana Béné, Sophie Gautier, Aurélie Grandvuillemin, Christine Le Beller, Chouki Chenaf, Nicolas Etienne, Solenn Brousseau, Alexis B. Cortot, Laurent Mortier, Delphine Staumont-Sallé, Franck Morschhauser, Alexandra Forestier, Matthieu Groh, David Launay, Eric Hachulla, Myriam Labalette, Jean-Emmanuel Kahn, Guillaume Lefèvre
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
eosinophilia
immune-related adverse events
emergent adverse event
immune checkpoint inhibitors
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1722022

Internet

http://dx.doi.org/10.1080/2162402X.2020.1722022

Similar Items